US Automated Breast Ultrasound Systems Market

U.S. Automated Breast Ultrasound Systems Market Size

The U.S. automated breast ultrasound systems market size was valued at USD 758.3 million in 2024 and is projected to grow from USD 855.9 million in 2025 to USD 3.3 billion by 2034, growing at a CAGR of 16%, according to the latest report published by Global Market Insights Inc. The U.S. market is experiencing significant growth, driven by the increasing prevalence of breast cancer in the U.S., rising technological advancements in automated breast ultrasound systems, growing reimbursement support from government agencies, and heightened awareness, along with favorable government initiatives regarding breast cancer.

Automated breast ultrasound systems (ABUS) are advanced imaging technologies that provide comprehensive 3D visualization of breast tissue, making them particularly beneficial for women with dense breasts. These systems are increasingly being adopted in clinical environments such as hospitals, diagnostic centers, and breast care clinics. Key players in the ABUS market include GE Healthcare, Siemens Healthineers, Koninklijke Philips, Hologic, and SonoCine. With leading companies driving innovation and integrating ABUS into clinical workflows, the technology is becoming a vital tool in enhancing early breast cancer detection and improving patient outcomes across the U.S. healthcare landscape.

The market grew from USD 542.2 million in 2021 to USD 675.5 million in 2023. This growth is primarily attributed to the rising incidence of breast cancer and growing innovation in automated breast ultrasound systems. Recent advancements include AI-powered diagnostic tools that categorize tumors with high accuracy, portable 3D scanners, and integration with digital breast tomosynthesis (DBT) to enhance detection rates. Additionally, the healthcare sector's emphasis on personalized and patient-centric diagnostics has positioned ABUS as a valuable complement in the U.S. market, offering enhanced lesion detection, reduced operator dependency, and improved breast cancer diagnostics, the market for which is estimated to reach USD 66.9 billion by 2032.

Technological advancements in automated breast ultrasound systems (ABUS) are transforming breast imaging by providing standardized, high-resolution 3D scans that significantly enhance lesion detection, particularly in women with dense breast tissue. These systems reduce reliance on operator skill, ensuring consistent and reproducible results across screenings, while offering a more comfortable and non-invasive alternative to traditional mammography. A notable example is Supersonic Imagine’s SuperSonic MACH 40, which combines advanced imaging precision with improved patient comfort. This innovation highlights a broader shift toward patient-centered healthcare, focusing on accurate and less-invasive diagnostic solutions. As awareness of breast cancer grows and the limitations of conventional imaging become more evident, hospitals and imaging centers are increasingly adopting ABUS to meet evolving clinical standards and patient expectations.

Additionally, the rising prevalence of invasive breast cancer is one of the key factors driving the growth of the U.S. automated breast ultrasound systems market. For instance, according to the American Cancer Society, in 2024, approximately 310,720 new invasive breast cancer cases are expected to be diagnosed among women in the U.S., 16% of which will be in women younger than 50 years of age. These statistics highlight the need for advanced diagnostic tools. Automated breast ultrasound systems, especially those equipped with digital and AI capabilities, are increasingly being adopted by hospitals and other end users worldwide to improve their screening capabilities.

ABUS is a specialized screening technology designed to detect breast cancer in women with dense breast tissue. Unlike traditional handheld ultrasounds, ABUS uses a wide, automated transducer to capture standardized, high-resolution 3D images of the entire breast. This approach reduces operator dependency and ensures more consistent results.

U.S. Automated Breast Ultrasound Systems Market Trends

• Global efforts to combat breast cancer increasingly rely on heightened awareness and the expansion of screening programs. Public health campaigns, media outreach, and educational initiatives play a crucial role in informing communities about symptoms, risk factors, and the importance of early detection.
  
• Programs such as the CDC’s National Breast and Cervical Cancer Early Detection Program, which has facilitated screenings for over 6 million women, are accelerating the adoption of advanced technologies, such as ABUS, into routine protocols.
  
• With an increasing prevalence of breast cancer in the U.S., targeted campaigns leverage ABUS to enhance diagnostic accuracy, promote annual screenings, and reduce mortality rates. The integration of ABUS with AI-powered diagnostics is emerging as a cornerstone of modern breast cancer screening, offering precise and reproducible imaging that supports radiologists in making earlier and more confident diagnoses.
  
• Furthermore, ABUS proves highly effective in the early detection of breast cancer, especially for women with dense breast tissue. To boost adoption and accessibility, healthcare systems deploy mobile ABUS units, peer education, and culturally tailored outreach. These strategies not only expand screening coverage but also drive market growth for advanced automated imaging technologies.
  

U.S. Automated Breast Ultrasound Systems Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

The U.S. market was valued at USD 542.2 million in 2021. The market size reached USD 675.5 million in 2023, from USD 604.3 million in 2022. Based on the product, the U.S. market is segmented into automated breast ultrasound system (ABUS), automated breast volume scanner (ABVS), and other products. The ABUS segment was valued at USD 482.3 million in 2024 and is projected to reach USD 2.1 billion by 2034, growing at a CAGR of 16.2%.

The growth is driven by rising demand for AI-powered imaging solutions, increased awareness of breast cancer screening, and the expanding use of ABUS in hospitals and diagnostic centers across the U.S. In comparison, the ABVS segment, valued at USD 250.1 million in 2024, is expected to grow to USD 1 billion by 2034, at a CAGR of 15.7%. Its technology’s integration with AI and digital platforms further boosts its appeal by enabling faster interpretation and better clinical outcomes.

• Automated breast volume scanners (ABVS) provide high-resolution, three-dimensional imaging of the entire breast, making them especially effective for detecting abnormalities in women with dense breast tissue.
  
• A notable example of this technology is the ACUSON S2000 ABVS by Siemens Healthineers, which combines automated scanning with advanced imaging capabilities to deliver comprehensive breast volume assessments. This system enhances diagnostic accuracy while improving workflow efficiency in hospitals and imaging centers.
  
• Additionally, the ABVS system, integrated with artificial intelligence, offers fast, reliable, and patient-friendly imaging through a digital platform. It stands out as a superior clinical imaging solution for healthcare providers. Since breast cancer remains the most prevalent cancer among women in the U.S., the demand for advanced diagnostic tools such as ABVS continues to grow, driving significant market expansion.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the U.S. automated breast ultrasound systems market is segmented into hospitals, diagnostic imaging centers, and specialty clinics. In 2024, diagnostic imaging centers held a share of about 30.1% and is expected to grow with a CAGR of 16.3% through 2034.

• Diagnostic imaging centers segment has emerged as the fastest-growing segment in the automated breast ultrasound system (ABUS) market, driven by their ability to deliver highly accurate and specialized imaging. These centers play a pivotal role in breast cancer screening programs, particularly for women with dense breast tissue, where ABUS offers a clear advantage over traditional mammography.
  
• The automated functionality and user-friendly design of ABUS aligns seamlessly with the operational needs of imaging centers. By enabling consistent, high throughput scanning with minimal specialized training, ABUS supports efficient workflows and enhances patient care. Whether used for routine screenings or targeted evaluations, ABUS facilitates timely and precise assessments, which are critical for early cancer detection and streamlined follow-up procedures.
  
• Furthermore, diagnostic imaging centers are equipped with advanced imaging technologies that provide high-resolution visualizations, significantly improving the accuracy of cancer diagnosis. These centers often serve as the first point of contact in identifying malignant conditions, reinforcing their importance within the broader healthcare ecosystem.
  

U.S. Automated Breast Ultrasound Systems Market Share

• The top 5 players, such as GE Healthcare, Hologic, Siemens Healthineers, SonoCine, and Koninklijke Philips, collectively held 60% of the total market share. These firms maintain their leadership through a strategic combination of technological innovation, clinical reliability, and market responsiveness. They consistently invest in advanced imaging technologies, such as 3D ultrasound, AI-powered diagnostics, and ergonomic system designs that enhance accuracy and patient comfort, particularly for women with dense breast tissue.
  
• The GE Invenia ABUS 2.0 is designed with advanced ergonomics to improve both patient comfort and clinician workflow. The system provides automated 3D imaging, ensuring consistent results while reducing operator fatigue. Its ergonomic scanning arm allows smooth maneuverability, and the AI-powered workflow tools streamline image review and reporting processes.
  
• Leading players in the U.S. market are driving growth by developing automated ultrasound systems that utilize AI technologies to deliver consistent, high-resolution 3D breast images. This technology enhances the accuracy of breast ultrasound, particularly for women with dense breast tissue.
  
• The ABUS market is evolving with trends such as AI-integrated imaging systems, radiomics-enabled platforms, and tools that streamline diagnostic workflows. These advancements are driven by the increasing need for early-stage breast cancer detection, particularly for women with dense breast tissue, and a global shift toward more personalized and less invasive screening options.
  

U.S. Automated Breast Ultrasound Systems Market Companies

Few of the prominent players operating in the U.S. automated breast ultrasound systems industry include:

• Canon
• CapeRay Medical
• Delphinus Medical Technologies
• GE Healthcare
• Hitachi
• Hologic
• Koninklijke Philips
• MetriTrack
• QView Medical
• SonoCine
• Supersonic Imagine
• Siemens Healthineers
• Seno Medical Instruments
• Shantou Institute of Ultrasonic Instruments
• Theraclion
  
  
• Hologic

Siemens Healthineers holds a significant share in the U.S. market through its comprehensive product portfolio. Siemens Healthineers emphasizes R&D and product development offerings with advanced imaging capabilities, ergonomic designs, and AI-powered diagnostic tools.

• Koninklijke Philips

Koninklijke Philips has a robust geographical presence, which enables it to enhance its market reach. Koninklijke Philips operates in more than 100 countries, thus comprising a strong distribution network.

• Siemens Healthineers

Siemens Healthineers holds a significant share in the U.S. market through its comprehensive product portfolio. Siemens Healthineers emphasizes R&D and product development offerings with advanced imaging capabilities, ergonomic designs, and AI-powered diagnostic tools.

U.S. Automated Breast Ultrasound Systems Industry News:

• In March 2023, MetriTrack announced a distribution partnership with Storage Solutions Technology Group, Inc. (SST Group), granting SST the rights to distribute and support the BVN-2000 Breast Volume Navigator system across all segments of the radiology market in the Midwestern U.S. This strategic collaboration expanded MetriTrack’s market reach, improved product accessibility, and strengthened its presence in breast ultrasound imaging.
  

The U.S. automated breast ultrasound systems market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021-2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Automated breast ultrasound system (ABUS)
• Automated breast volume scanner (ABVS)
• Other products

Market, By End Use

• Hospitals
• Diagnostic imaging centers
• Specialty centers